Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Endostar plus TEC as neoadjuvant chemotherapy for stage III breast cancer
ChiCTR-TRC-11001424Phase 4Completed
- Sponsor
- The Fourth Hospital of Hebei Medical University
- Start
- Jun 2011
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of endostar, docetaxel, epirubicin and cyclophosphamide in breast cancer (2 arms), sponsored by The Fourth Hospital of Hebei Medical University. Primary endpoints: pathological complete response rate and clinical efficacy. Started Jun 2011; status: completed.
02
Drugs
endostardocetaxelepirubicincyclophosphamide
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR-TRC-11001424.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TRC-11001424.